Home > Search Results

Results: 9

Clear

The study found that trials comparing different settings for delivering intravenous chemotherapy appear difficult to conduct. Consequently, few conclusions can be reached regarding the clinical effectiveness and cost-effectiveness of the home, community and outpatient settings. Future studies could produce more informative data if careful consideration is given to study design.

Health Services and Delivery Research - NIHR Journals Library.

Version: April 2015

Some women have non‐cancerous growths of the uterus, called fibroids. In a third of cases the fibroids produce symptoms, such as vaginal bleeding, that warrant treatment. The surgical removal of the fibroids, called myomectomy, is one of the treatment options for fibroids. It can be accomplished by either laparotomy (through an incision into the abdomen) or laparoscopy (keyhole surgery). The procedure is associated with heavy bleeding. Many interventions have been used by doctors to reduce bleeding during an operation for removing fibroids but it is unclear whether or not the interventions are effective.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: August 15, 2014

This guidance updates and replaces NICE clinical guideline 24 (published February 2005).

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: April 2011

To evaluate the comparative effectiveness of interventions (intravenous [IV] fluids, N-acetylcysteine, sodium bicarbonate, and statins, among others) to reduce the risk of contrast-induced nephropathy (CIN), need for renal replacement therapy, mortality, cardiac complications, prolonged length of stay, and other adverse events after receiving low-osmolar contrast media (LOCM) or iso-osmolar contrast media (IOCM).

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: January 2016

The term “cancer of unknown primary” refers to a condition in which a patient has metastatic malignancy without an identified primary source. This is a very heterogeneous disease in which the type of tumour, the extent of spread, and the outcome of treatment all vary widely. When categorising patients with cancer of unknown primary, one important factor initially considered is the cell type of origin of the metastatic disease. The majority of patients have malignancy which appears to derive from epithelial cells, and hence are regarded as having carcinoma of unknown primary. Patients with tumours of non-epithelial lineage (melanoma, sarcoma, lymphoma, germ-cell) form a distinct and important minority, since subsequent management can often be satisfactorily undertaken even in the absence of an identifiable primary source. Such patients are not considered in this guideline, since their care is adequately defined in existing guidelines for their specific tumour type. The term “carcinoma of unknown primary” (CUP) is used henceforth to refer to those patients with metastatic malignancy of epithelial, neuroendocrine or undifferentiated lineage whose investigation and management is considered within the scope of this guideline.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: July 2010

Non-Hodgkin's lymphoma is the sixth most common cancer in the UK. There are many different subtypes of the disease, with markedly different clinical courses and requirements for therapy. Diagnosing non-Hodgkin's lymphoma and the precise subtype is challenging, and optimising the diagnostic process is central to improved management. Significant improvements in our understanding of the biology of non-Hodgkin's lymphoma have contributed to improved diagnosis and also allowed for more targeted therapies.

NICE Guideline - National Guideline Alliance (UK).

Version: July 2016

The authors found that laparoscopic treatment of endometriosis reduced pain and improved fertility. Co-interventions that may help (in appropriate circumstances) included laparoscopic presacral neurectomy, pre-operative and/or postoperative hormonal suppression, excisional cystectomy with mesna and/or initial circular excision and anti-adhesive barriers. Due to methodological problems in the review, particularly the failure to assess study quality, the conclusions should be regarded cautiously.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

This review assessed systemic treatments for advanced uterine sarcoma. The authors concluded that offering palliative chemotherapy to these patients is reasonable, that the response rate to treatment appears to vary with histological type, and that further research is required. There were limitations to the review, but the authors' cautious conclusions appear to reflect the limited evidence.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2005

This review evaluated evidence on dose-intensive chemotherapy for adult patients with locally advanced or metastatic soft tissue sarcoma. The authors concluded that they could not discern any consistent benefits for high-dose over standard-dose chemotherapy in these patients. Although relevant non-English studies may have been overlooked, on the basis of the evidence retrieved, the authors’ conclusions appear appropriate and broadly reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Systematic Reviews in PubMed

See all (15)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...